| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
ODN-1668 targets Toll-like receptor 9 (TLR9). It is a Class B CpG ODN that contains a fully phosphorothioated (PS) backbone with one or more CpG dinucleotides. Activation of TLR9 triggers MyD88-dependent signaling, leading to B cell activation, TNF-alpha secretion, and Th1-polarized immune responses.
|
|---|---|
| ln Vitro |
Polyclonal B cell activation is promoted by ODN 1668, which also causes TNF-α secretion[1].
ODN-1668 induces TNF-alpha secretion and promotes polyclonal B cell activation in vitro. It is an immunostimulatory sequence that upregulates IgM levels and induces an antimicrobial immune response via a CaTLR9-dependent pathway, demonstrating strong immunomodulatory properties in cell-based assays. |
| ln Vivo |
Protein antigen responses are stimulated by ODN 1668 (10 nmol)[1]. Rats treated once with ODN 1668 (1 or 5 mg/kg; ip or sc) experience mild fever and anorexia[2].
In vivo, ODN-1668 (10 nmol) stimulates immune responses to protein antigens when used as a vaccine adjuvant. At 1 or 5 mg/kg (i.p. or s.c.), it causes moderate fever and anorexia in rats. It has also been shown to induce an antimicrobial immune response via a CaTLR9-dependent pathway. |
| Enzyme Assay |
Not applicable. ODN-1668 is an oligonucleotide agonist that binds to and activates the intracellular TLR9 receptor. Activity is measured in cell-based activation assays rather than cell-free receptor binding experiments.
|
| Cell Assay |
Primary immune cells or TLR9-expressing cell lines are seeded in plates. ODN-1668 is added to culture medium at concentrations of 0.1-10 uM for 18-24 hours. TNF-alpha and other cytokine levels in the supernatant are quantified by ELISA. B cell activation is assessed by flow cytometry (e.g., CD69, CD86 expression).
|
| Animal Protocol |
Animal/Disease Models: C57BW6 mice[1]
Doses: 10 nmol Route of Administration: 300 μg OVA (ovalbumin) in PBS or liposomes containing OVA were injected with or without 10nmol ODN in the hind footpads of C57BW6 mice. A boost of the same inoculum was given at 2 weeks, and 1 week later blood was taken for serum antibody titering. Experimental Results: Strongly potentiated the antibody response and induced class switching toward IgG2a and IgG2b. demonstrated B cell blast formation and a more than twofold increase in B7.2 (CD86) and IL-2 receptor-α (CD25 ) surface expression. Animal/Disease Models: Male Wistar rats with body weights in the range of 175–200 g[2] Doses: 1 mg/kg or 5 mg/kg Route of Administration: intraperitoneal (ip)and subcutaneous (sc) injection, once Experimental Results: Caused moderate fever and anorexia . Induced a significant increase of IL-6. Increased expression of inflammatory genes and activated inflammatory transcription factors. In a typical protocol, C57BL/6 mice receive ODN-1668 at 10 nmol (approx. 50 ug) by intraperitoneal or subcutaneous injection, often formulated with 300 ug OVA in PBS or liposomes. Blood and lymphoid tissues (spleen, lymph nodes) are collected for assessing antigen-specific immune responses via ELISA, ELISpot, or flow cytometry. |
| ADME/Pharmacokinetics |
Detailed PK data are limited. ODN-1668 is administered via i.p. or s.c. routes. Its fully phosphorothioated backbone enhances nuclease resistance, leading to a longer half-life (hours) compared to unmodified DNA. Distribution: accumulates in lymphoid tissues. Storage: -20degC, powder; -80degC, in solvent.
|
| Toxicity/Toxicokinetics |
Standard oligonucleotide safety precautions apply. ODN-1668 is for research use only. Systemic administration may induce dose-dependent pro-inflammatory effects (e.g., fever, anorexia). Avoid inhalation and contact. Use PPE in a well-ventilated area.
|
| References |
|
| Additional Infomation |
This is a research-grade immunostimulatory TLR9 agonist. It is used in vaccine adjuvant research and as a reference standard for CpG ODNs. Sequence: 5‘-tccatgacgttcctgatgct-3'. Also available in biotin-labeled or FITC-labeled forms. For research use only, not for clinical therapy.
|
| Molecular Formula |
NA??MOLECULARWEIGHT
|
|---|---|
| Molecular Weight |
0
|
| CAS # |
1186063-66-0
|
| Related CAS # |
Biotin-labeled ODN 1668 sodium;FITC-labeled ODN 1668 sodium
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 20 mg/mL (~3.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
